Car-t cell therapy for relapsed b-cell leukemia or lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell therapy called CAR-T cells that are designed to find and destroy cancer cells with the CD19 or CD22 markers. The goal is to see if this experimental treatment can help people with B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with B-cell acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL).
- Your cancer cells must have a specific marker (CD19 or CD22), which your doctor can check.
- Your cancer has come back or hasn't improved with standard treatments.
- Your heart, lungs, liver, and kidneys are working well enough, and you are generally able to take care of yourself (ECOG score of 0 or 1).
- You cannot be pregnant or breastfeeding, and you must agree to use contraception for at least 1 year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial tests a new type of immunotherapy called CAR-T cell therapy that targets a protein (CD19) on cancer cells. It is for people with B-cell leukemia or lymphoma that has not responded to standard treatment or has come back, and the goal is to help their immune system fight the cancer.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.
Hear when a new R/R NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.